A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

NCT06901349 on ClinicalTrials.gov · last registry update 2025-09-24

Withdrawn before anyone was enrolled. The sponsor logged completion for 10 June 2025. Primary outcome, as filed: Percent Change from Baseline in Body Weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 0
Started: 2025-05-23
Primary completion: 2025-06-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change from Baseline in Body Weight

Conditions studied

Obesity · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.